Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib + Obinutuzumab in CLL/SLL Post-BTKi
NCT02292225Phase 1Terminated
- Sponsor
- Secura Bio
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of duvelisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Secura Bio. Primary endpoints: Dose-limiting toxicities at 28 days and Treatment-emergent adverse events. Started Feb 2015; status: terminated.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02292225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292225.